Form 4: OnKure Therapeutics Director to Acquire Shares Through Pre-Planned RSU Grant

OnKure Therapeutics, Inc. Director Edward T Mathers is scheduled to acquire 4,694 shares of Class A Common Stock through a pre-planned restricted stock unit grant on June 30, 2025, which will bring his total direct beneficial ownership to 7,274 shares.

Summary

• Edward T Mathers, a Director and 10% Owner of OnKure Therapeutics, Inc. (OKUR), is scheduled to acquire 4,694 shares of Class A Common Stock.
• The acquisition is set to occur on June 30, 2025, as a pre-planned transaction under a Rule 10b5-1(c) plan.
• These shares will be acquired as fully vested restricted stock units (RSUs) at a price of $0 per share.
• The RSUs are granted in lieu of a quarterly cash retainer, as elected by Mr. Mathers, under the company's Outside Director Compensation Policy.
• Following this transaction, Mr. Mathers will directly beneficially own 7,274 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, especially through an election to receive equity over cash and via a pre-planned transaction, generally indicates positive sentiment and alignment of interests, though it's a routine compensation event.

Positives

• Director Edward T Mathers elected to receive equity (restricted stock units) instead of a cash retainer, indicating confidence in OnKure Therapeutics, Inc.'s future performance.
• The transaction is pre-planned under a Rule 10b5-1(c) plan, which demonstrates a structured approach to insider trading compliance and transparency.
• The acquisition will increase the director's direct beneficial ownership, aligning his interests further with shareholders.

Future Outlook

This Form 4 filing reports a pre-planned future transaction under a Rule 10b5-1(c) plan, indicating that Director Edward T Mathers will acquire 4,694 shares of Class A Common Stock on June 30, 2025. This transaction is part of the company's director compensation policy, where equity is granted in lieu of cash.

Management Comments

• These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy.

Industry Context

This insider transaction reflects a common practice in corporate governance where directors receive equity compensation. The use of a Rule 10b5-1(c) plan for pre-scheduled transactions is also a standard practice for insiders to manage their equity holdings in compliance with securities laws.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as restricted stock units, is a standard industry practice across publicly traded companies, aligning director interests with shareholder value.
• The utilization of a Rule 10b5-1(c) plan for pre-scheduled equity transactions is a widely adopted best practice for corporate insiders to mitigate concerns about trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in director equity ownership aligns the director's interests more closely with those of the shareholders, potentially fostering better long-term decision-making.
• Employees: No direct impact on employees is indicated by this transaction.
• Customers: No direct impact on customers is indicated by this transaction.
• Suppliers: No direct impact on suppliers is indicated by this transaction.
• Creditors: No direct impact on creditors is indicated by this transaction.

Next Steps

• The reported transaction is scheduled to occur on June 30, 2025, as per the Rule 10b5-1(c) plan.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity grant, beneficial ownership, Rule 10b5-1